Brind.

Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.

2 reports, 1 independent Updated Aug 12

Gone quiet

Reports: 2
Developments: 3
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.

Who's involved

What this event is mainly about

FDA Altimmune, Inc.mash

How it developed

Newest first. Tap a step to see who reported it.

Aug 12Altimmune's Pemvidutide received Breakthrough Therapy Designation from the FDA.Sub-event
Jul 28Altimmune, Inc. is seeking an End-of-Phase 2 meeting with the FDA regarding the results of pemvidutide trials for MASH.Sub-event
Jul 9Altimmune advances MASH treatment with Pemvidutide and receives analyst attention.

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Altimmune, Inc.
American biopharmaceutical company
- X4 Pharmaceuticals and Altimmune, Inc. are small-cap healthcare companies trading on the Nasdaq stock exchange.Thu 14:20
mash
fast genome and metagenome distance estimation using MinHash
- Wave Life Sciences is developing WVE-007, an investigational GalNAc-siRNA product, for MASH indications.Wed 12:44

Related events

Coverage

Newest first; wire copies grouped

Aug 12themarketsdaily.com
Jul 9Unknown outlet